Axsome Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Great. Good day, everybody. My name is Ash Verma. I cover SMID Cap Biotech and Spec Pharma at UBS. Welcome to the UBS Biopharma Conference in London. Really excited to have Axsome Therapeutics. Mark, Nick, thank you so much for joining us. Maybe, I know there's been a lot of focus on the AD agitation launch. You just reported third quarter earnings. If you can hit some of the highlights on how you see the path for growth from here.
Sure. Thanks for having us, Ash. Do you want to talk some of the highlights?
Sure. Thank you. Yeah, thanks for having us, Ash.
Maybe just start on the financials. $280 million in total net sales for the quarter. That puts us in a over a billion-dollar runway for the first time ever. A run rate, I should say. So, really pleased with that. That's led by AUVELITY, which did $208 million, 53% year-over-year, continuing to grow at a very nice pace. We see continued growth in MDD, the underlying business, which actually grew at a faster pace year-over-year in Q3 than versus Q2, looking at the just scripts as well as the revenue for under 65, which we've been using as a proxy for MDD. Then AD agitation growing at a really nice pace, doubling in script growth quarter-over-quarter. So, really pleased from that perspective.
Additionally, doesn't get too much talked about, but SUNOSI had $48 million in revenue for the quarter. That included an $8.5 million milestone payment, but continuing to grow very nicely. SYMBRAVO did just around $4 million for the quarter, continuing to grow in scripts. Really pleased to see where that's going to take us in the next year or two.
Maybe just some qualitative commentary too on state of affairs for AUVELITY and starting with AD agitation, just to complement what Nick shared on the numbers. Feedback so far has been very positive from prescribers, so those who have prescribed the product since following approval, which is great. Feedback on the tolerability profile and the efficacy profile in line with the label. Very, very pleased with that. Of course, that's very important, and indicates kind of where the North Star is for potential utilization and uptake and patient profiles and the opportunity there to impact that indication. We're very, very excited. Of course, it's still early days, but it's growing. The base business in MDD is growing, and the utilization there continues to move up in lines of therapy. It's primarily monotherapy utilization now. It's primarily first and second line utilization.
It's been there for some time, but those continue to grow quarter-over-quarter. We really like that, and we're really excited about continued uptake. We've seen the uptake in leading indicators in AD agitation and continued growth leading indicators in the base business for major depressive disorder. That corresponds to, in addition to the label expansion, so the new indication being added to the label, the expansion in the sales team that we did earlier this year too. We're seeing the impact of both of those, and we expect those to continue to grow over time.
Yeah. Really, really pleased with the state of affairs and outlook.
Yeah, thanks for that. Maybe, I know you have provided lots and lots of metrics about Alzheimer's disease agitation. If you had to hit maybe like one or two, the most important ones that gives you the conviction that the growth is going to sort of be more well perceived by investors, what would you focus on?
Yeah, go ahead. Yeah, maybe I'll start with our leading indicator for growth is NBRxs.
What you've seen to date is the TRxs and the work that has gone into getting AUVELITY to where it's at today, the 208 million, and that's built on the NBRxs that you saw really starting in 2025 into 2026. We've shared is NBRxs continue to grow, and they've actually grown north of 200% year over year, going from 2,400 on average per month. I'm sorry, per week, per month in, 2,400 per week in Q1 to 3,600, actually hit 3,800 in October. Really pleased with that trajectory. That is filling the pipeline. When we talk about future growth, that is your leading indicator. The other piece of future growth is just the pure team that we've built, right?
We built that 208 million on a field force team of, call it, less than 300 reps. We started the year with around 270 reps, growing that team to now north of 650 if you include the long-term care team. Setting up that infrastructure and setting us up for success in future growth is really important. That's why we feel very convicted in how we expect to even further grow the team. We talked about NBRxs in totality as well, specifically for AD agitation. We included a chart this time on the corporate deck that showed NBRxs in AD agitation, which we're using 65 and older as a proxy, have grown 260%. They were on average 1,000 per month from 2025, beginning of 2025, until we had the approval in April 2026. They've grown from 1,000 to now 3,600 NBRxs per month.
In a very, very short period of time, and that number is continuing to grow. Really pleased with that. That is how we think about the future performance. Then, I would say maybe lastly is direct-to-consumer advertising. We have been very focused on how we have thought about DTC, specifically on TV, but continuing to invest in there. What we would anticipate is with the larger field team, we would anticipate that we would have a higher ROI because we are going to get more pull-through. Doctors will be more aware, consumers coming in asking for it, so you will see a higher ROI as it relates to that.
Got it. Great. Based on the Q3 sales that you have outlined, is there a way for you to break down how much of that could have come from AD agitation as opposed to MDD?
Sure. Yeah. As I shared, what we have now included is over and under 65. To be clear, we do not have any better information internally by indication. We ship the product to our wholesalers, we ship AUVELITY then gets shipped to the pharmacies, and then pharmacies dispense it. There is no clean-cut, black-and-white way to say, "Hey, this is an ADA script," or, "This is an MDD script." There is some data that is out there, but it is limited in the amount of capture, so it does not permit you to say very delineated ADA or MDD. What is clearly delineated is the script data that shows age. What we have now shared is over and under 65, and we are able to see that over 65 in Q3 was roughly 13.5% of the total scripts for AUVELITY.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
